04 February 2019 by Tegan Dunmall

Long-term benefits of intravenous epoprostenol in idiopathic pulmonary arterial hypertension - a personal experience

Idiopathic pulmonary arterial hypertension (PAH) is a rare medical condition with considerable morbidity and mortality.

Over the last 15 years, medical therapy has been shown to  improve outcomes, including survival, functional status and quality of life. Intravenous Epoprostenol is a treatment inititated when a patient's response to oral therapy is inadequate, usually before consideration of lung transportation.


About the author

profile picture of Tegan Dunmall

Tegan Dunmall


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI